Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance

Evaluation of the Safety and Effects on Glycemic Control of Medical Food Formulation WBF-0031 in Subjects With Abnormal Glucose Tolerance

NCT04490460•Eden Miller

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Abnormal Glucose Tolerance

Interventions

WBF-0031

Locations

United States

Locations (1)

Diabetes and Obesity Care

Bend, Oregon, United States

Key Dates

Start Date

June 1, 2020

Primary Completion Date

February 1, 2021

Completion Date

February 28, 2021

Last Updated

July 29, 2020

Sponsors

Lead Sponsor

Eden Miller

Collaborators

Pendulum Therapeutics

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions